| First Author | Westmark PR | Year | 2018 |
| Journal | Neurobiol Dis | Volume | 119 |
| Pages | 190-198 | PubMed ID | 30125640 |
| Mgi Jnum | J:268588 | Mgi Id | MGI:6267178 |
| Doi | 10.1016/j.nbd.2018.08.008 | Citation | Westmark PR, et al. (2018) Rescue of Fmr1(KO) phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056. Neurobiol Dis 119:190-198 |
| abstractText | Metabotropic glutamate receptor 5 (mGluR5) is a drug target for central nervous system disorders such as fragile X syndrome that involve excessive glutamate-induced excitation. We tested the efficacy of a novel negative allosteric modulator of mGluR5 developed by Merz Pharmaceuticals, MRZ-8456, in comparison to MPEP and AFQ-056 (Novartis, a.k.a. mavoglurant) in both in vivo and in vitro assays in a mouse model of fragile X syndrome, Fmr1(KO) mice. The in vivo assays included susceptibility to audiogenic-induced seizures and pharmacokinetic measurements of drug availability. The in vitro assays included dose response assessments of biomarker expression and dendritic spine length and density in cultured primary neurons. Both MRZ-8456 and AFQ-056 attenuated wild running and audiogenic-induced seizures in Fmr1(KO) mice with similar pharmacokinetic profiles. Both drugs significantly reduced dendritic expression of amyloid-beta protein precursor (APP) and rescued the ratio of mature to immature dendritic spines. These findings demonstrate that MRZ-8456, a drug being developed for the treatment of motor complications of L-DOPA in Parkinson's disease and which completed a phase I clinical trial, is effective in attenuating both well-established (seizures and dendritic spine maturity) and exploratory biomarker (APP expression) phenotypes in a mouse model of fragile X syndrome. |
